MedTrace Logo

Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction

NCT06143787 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2024-08-01

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of Tranexamic Acid Oral Solution 5% in patients treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple tooth extraction.

Conditions

  • Bleeding From Teeth
  • Bleeding Prophylaxis

Interventions

DRUG

Tranexamic acid

7 days Oral rinsing following tooth extraction

Sponsors & Collaborators

  • Hyloris Developments

    lead INDUSTRY

Principal Investigators

  • Todd Bertoch, Dr. · JBR Clinical Research (CenExcel)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-07
Primary Completion
2024-12-27
Completion
2024-12-27
FDA Drug
Yes

Countries

  • United States
  • Croatia
  • Hungary
  • Romania
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06143787 on ClinicalTrials.gov